Invex Therapeutics Unveils Promising Alzheimer’s Treatment Results

Invex Therapeutics Ltd. (AU:IXC) has released an update.

Invex Therapeutics Ltd. has announced promising results from their collaboration with Tessara Therapeutics, showing that Exenatide significantly improves neuronal cell survival in a 3D human brain model of Alzheimer’s Disease. The study highlights Exenatide’s potential in increasing cell viability and its role as a GLP-1 receptor agonist in protecting against Alzheimer’s, a market valued at $17 billion in 2023. These findings could pave the way for further exploration of Exenatide in treating other neurodegenerative diseases.

For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.